Metastatic cancer remains one of the most challenging stages of cancer, with the disease spreading to other organs, often leading to severe outcomes for patients. While scientists have made significant advances in understanding cancer biology, the exact mechanisms by which prostate cancer spreads have long remained elusive. However, a recent collaborative study between Cold Spring Harbor Laboratory (CSHL) and Weill Cornell Medicine offers a new approach to understanding this process.
Researchers, led by CSHL Professor Adam Siepel, utilized cutting-edge barcoding technology to trace the pathways of prostate cancer metastasis. The approach provides a clearer understanding of how cancer spreads to various organs, highlighting both the rarity and significance of metastatic cells within tumors.
New Mouse Model and Barcoding Technology
The core of the research involved a novel mouse model known as Evolution in Cancer Prostate (EvoCaP) and an analysis pipeline named Evolutionary Lineage Tracing in R (EvoTraceR). This system allowed the team to genetically barcode individual cancer cells using short DNA sequences, enabling precise tracking of these cells as they moved through the body.
Previous methods, such as imaging techniques or whole-genome sequencing, often required extensive time and financial resources and didn’t always yield accurate information on cell movement. According to Siepel, “This barcoding lets us read off the precise tracing information about how the cancer has spread from its origin to the tissues to which it’s metastasized.”
The new method revealed that the majority of cancer cells remain confined within the primary tumor. However, a small subset of aggressive cells is responsible for metastasis, spreading to critical areas such as the bones, liver, lungs, and lymph nodes. This finding helps clarify why metastasis is rare but deadly when it occurs.
Collaboration and Future Directions
Armin Scheben, a postdoctoral researcher at CSHL, emphasized the potential for this foundational work to extend beyond prostate cancer. “We’ve laid the fundamental molecular biology foundation for a whole lot of other questions to be answered,” said Scheben. “This is the beginning phase of a much larger project where our colleagues are expanding this work to other types of cancer, and we start looking at therapeutic interventions for metastasis.”
The team’s method holds promise for developing targeted cancer treatments, as understanding the specific pathways that cancer cells use to metastasize could lead to new therapies aimed at preventing or slowing the spread of cancer.